Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | HTR1D | P28221 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027802 | 0.83 | MAOB (0.37) | MAOBDRD2HTR1DDRD3PTGS2 | |
| SCHEMBL2303778 | 0.82 | MEN1 (0.41) | PTGS2 | |
| SCHEMBL4809246 | 0.82 | MEN1 (0.41) | PTGS2 | |
| SCHEMBL4456861 | 0.82 | MAOB (0.36) | MAOBDRD2HTR1DDRD3PTGS2 | |
| SCHEMBL17977038 | 0.79 | CYP3A4 (0.48) | MAOBDRD2HTR1DDRD3PTGS2 | |
| SCHEMBL4816146 | 0.76 | HSD17B1 (0.54) | HSD17B1 | |
| SCHEMBL24362288 | 0.76 | MAOA (0.38) | MAOBHSD17B1DRD2DRD3PTGS2 | |
| SCHEMBL29600396 | 0.76 | MAOA (0.38) | MAOBHSD17B1DRD2DRD3PTGS2 | |
| SCHEMBL27087599 | 0.74 | DRD2 (0.35) | DRD2HTR1DDRD3 | |
| SCHEMBL29600467 | 0.74 | MAOA (0.38) | MAOBDRD2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1603885-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| WO-2004080973-A1 | FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | MAOB 3311/4885HSD17B1 2373/4885DRD2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.